BLCM · Bellicum Pharmaceuticals, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Revenue | $6.20M | - | $500.0K | $7.14M | $185.0K |
| Cost of Revenue | - | - | - | - | $864.0K |
| Gross Profit | - | - | - | - | ($679.0K) |
| R&D | $22.76M | $23.58M | $39.05M | $64.53M | $71.15M |
| SG&A | $5.72M | $7.01M | $15.53M | $29.97M | $25.00M |
| Total Operating Expenses | $28.48M | $30.59M | $54.58M | $94.51M | $96.59M |
| D&A | $11.0K | $105.0K | $1.47M | $6.70M | $6.70M |
| Operating Income | ($26.98M) | ($24.87M) | ($51.69M) | ($87.36M) | ($95.47M) |
| Interest Expense | - | $4.0K | $2.66M | $4.28M | $4.20M |
| Income Tax | $0 | - | - | - | - |
| Net Income | ($24.97M) | ($9.71M) | ($7.72M) | ($112.48M) | ($98.04M) |
| EPS - Basic | ($0.81) | ($1.34) | - | - | - |
| EPS - Diluted | ($0.81) | ($1.34) | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | $21.84M | $46.16M | $35.49M | $91.03M | $43.70M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | $486.0K | $90.0K | $891.0K | $2.64M | $3.77M |
| Current Assets | $23.80M | $49.13M | $39.44M | $111.85M | $95.30M |
| Total Assets | $23.82M | $49.14M | $40.58M | $116.25M | $121.50M |
| Current Liabilities | $3.77M | $6.71M | $24.70M | $94.42M | $15.80M |
| Long-term Debt | - | - | $0 | $25.72M | $35.83M |
| Total Liabilities | $3.77M | $6.71M | $25.05M | $121.00M | $53.02M |
| Stockholders' Equity | $2.02M | $24.39M | ($2.50M) | ($26.22M) | $68.48M |
| Retained Earnings | ($575.42M) | ($550.45M) | ($540.75M) | ($533.02M) | ($420.55M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($25.78M) | ($23.11M) | ($56.65M) | ($77.57M) | ($74.78M) |
| Investing Cash Flow | ($21.0K) | $893.0K | $14.08M | $48.86M | $10.41M |
| Financing Cash Flow | $0 | $32.87M | ($14.24M) | $74.09M | $68.11M |
| CapEx | $21.0K | $7.0K | $625.0K | $522.0K | $1.62M |
| Free Cash Flow | ($25.80M) | ($23.11M) | ($57.27M) | ($78.09M) | ($76.40M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | -367.0% |
| Operating margin | -435.2% | - | -10338.4% | -1223.1% | -51603.2% |
| EBITDA margin | -435.0% | - | -10044.0% | -1129.3% | -47982.7% |
| Net margin | -402.8% | - | -1544.4% | -1574.6% | -52992.4% |
| Free cash flow margin | -416.2% | - | -11455.0% | -1093.3% | -41296.8% |
| FCF / Net income | 1.03 | 2.38 | 7.42 | 0.69 | 0.78 |
| R&D / Revenue | 367.2% | - | 7810.4% | 903.5% | 38460.5% |
| SG&A / Revenue | 92.2% | - | 3106.2% | 419.6% | 13512.4% |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -104.8% | -19.7% | -19.0% | -96.8% | -80.7% |
| Return on equity | -1239.4% | -39.8% | 309.3% | 429.0% | -143.2% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 6.31 | 7.32 | 1.60 | 1.18 | 6.03 |
| Quick ratio | 6.31 | 7.32 | 1.60 | 1.18 | 6.03 |
| Cash ratio | 5.79 | 6.88 | 1.44 | 0.96 | 2.76 |
| Leverage | |||||
| Debt / Equity | - | - | 0.00 | -0.98 | 0.52 |
| Debt / Assets | - | - | 0.00 | 0.22 | 0.29 |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | - | -6216.5x | -19.4x | -20.4x | -22.7x |
| Equity multiplier | 11.82 | 2.01 | -16.25 | -4.43 | 1.77 |
| Liabilities / Assets | 0.16 | 0.14 | 0.62 | 1.04 | 0.44 |
| Efficiency | |||||
| Asset turnover | 0.26 | - | 0.01 | 0.06 | 0.00 |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | 1594d |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | - | - | - | - | - |
| P / S | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | - | -93.0% | 3761.1% | - |
| Revenue CAGR (3y) | -4.6% | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | -8.5% | 51.9% | 40.8% | 8.5% | - |
| Net income growth (YoY) | -157.3% | -25.7% | 93.1% | -14.7% | - |
| EPS growth (YoY) | 39.6% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | -11.6% | 59.6% | 26.7% | -2.2% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | -91.7% | - | 90.5% | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$12.40M totalSupply Agreement And License Revenue$6.20M · 50.0%
License Revenue$5.50M · 44.4%
Supply Agreement$700.0K · 5.6%
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-22.89
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
0/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing BELLICUM PHARMACEUTICALS against the 5 most active filers in the same SIC group.